Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue

• Published in: Antimicrobial agents and chemotherapy Vol. 66; no. 8; p. e0043822
• Main Authors: Alshaer, Mohammad H., Barlow, Brooke, Maranchick, Nicole, Moser, Miriam, Gramss, Leon, Burgmann, Heinz, Jalali, Valentin Al, Wölfl-Duchek, Michael, Jäger, Walter, Poschner, Stefan, Plöchl, Walter, Reinprecht, Andrea, Rössler, Karl, Gruber, Andreas, Zeitlinger, Markus, Peloquin, Charles A., Hosmann, Arthur
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 16.08.2022
• Subjects: Anti-Bacterial Agents - pharmacokinetics; Antimicrobial Chemotherapy; Brain; Clinical Therapeutics; Critical Illness; Humans; Meropenem - pharmacokinetics; Monte Carlo Method; Prospective Studies; Thienamycins - pharmacokinetics; meropenem; pharmacokinetics; central nervous system infections; pharmacodynamics; Monte Carlo simulation
• ISSN: 0066-4804; 1098-6596; 1098-6596
• DOI: 10.1128/aac.00438-22

Meropenem is a broad spectrum carbapenem used for the treatment of cerebral infections. There is a need for data describing meropenem pharmacokinetics (PK) in the brain tissue to optimize therapy in these infections. Meropenem is a broad spectrum carbapenem used for the treatment of cerebral infections. There is a need for data describing meropenem pharmacokinetics (PK) in the brain tissue to optimize therapy in these infections. Here, we present a meropenem PK model in the central nervous system and simulate dosing regimens. This was a population PK analysis of a previously published prospective study of patients admitted to the neurointesive care unit between 2016 and 2019 who received 2 g of meropenem intravenously every 8 h. Meropenem concentration was determined in blood, cerebrospinal fluid (CSF), and brain microdialysate. Meropenem was described by a six-compartment model: two compartments in the blood, two in the CSF, and two in the brain tissue. Creatinine clearance and brain glucose were included as covariates. The median elimination rate constant was 1.26 h −1 , the central plasma volume was 5.38 L, and the transfer rate constants from the blood to the CSF and from the blood to the brain were 0.001 h −1 and 0.02 h −1 , respectively. In the first 24 h, meropenem 2 g, administered every 8 h via intermittent and extended infusions achieved good target attainment in the CSF and brain, but continuous infusion (CI) was better at steady-state. Administering a 3 g loading dose (LD) followed by 8 g CI was beneficial for early target attainment. In conclusion, a meropenem PK model was developed using blood, CSF, and brain microdialysate samples. An 8 g CI may be needed for good target attainment in the CSF and brain. Giving a LD prior to the CI improved the probability of early target attainment.